CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Bortezomib +5 moredrug
Likely dose
Bortezomib 1.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00634179
NCT00634179Phase 2Completed
CompareCT.gov

A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas

Emory University·interventional·Posted Mar 12, 2008·Updated Oct 27, 2016

In Brief

A Phase 2 clinical trial evaluating Bortezomib, Rituximab, and 4 other interventions for Lymphoma, B-Cell and Follicular Lymphoma. Completed, enrolled 37 participants across 1 site.

Detailed Summary

This is an open-label (doctors and patients know which drug will be given), single center, phase 1/2 clinical trial. The primary objective is to determine whether VR-CHOP provides benefit to patients with previously untreated indolent non-Hodgkin's lymphomas (NHL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, B-Cell, Follicular Lymphoma
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 12, 2008
Enrollment StartFeb 1, 2008
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 18.3 years ago

Interventions

Bortezomibdrug

Bortezomib 1.6 mg/m² given on days 1 and 8

Rituximabbiological

Rituximab 375 mg/m²

Doxorubicindrug

Doxorubicin 50 mg/m²

Cyclophosphamidedrug

Cyclophosphamide 750 mg/m²

Vincristinedrug

Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1

Prednisonedrug

Prednisone 100 mg/day given orally on days 1-5